Example: Heart Attack

Search clinical trials for: Caspofungin

Total 85 results

NCT03399032

Unknown status

Pharmacokinetics of Caspofungin

Conditions: Septic Shock; Fungal Infection; Critical Illness
NCT03798600

Completed

Pharmacokinetics/Pharmacodynamics (PK/PD) of Caspofungin in Intensive Care Unit (ICU) Patients. An Open Observational Study for Antifungal Treatment's Optimization

Conditions: Critical Illness; Infection
NCT03857399

Completed

Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin

Conditions: Fungal Infection
NCT02596984

Completed

Evaluation of the Pharmacokinetics of Caspofungin in ICU Patients

Conditions: Shock
NCT01533558

Completed

Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates

Conditions: Invasive Fungal Infection
NCT01968395

Completed

Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure

Conditions: Bacterial Infections and Mycoses; Liver Disease
NCT01318148

Completed

Pharmacokinetic, Safety and Efficacy of Intermittent Application of Caspofungin for Antifungal Prophylaxis

Conditions: Fungal Infection
NCT01499433

Unknown status

Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease

Conditions: Invasive Pulmonary Aspergillosis; Chronic Obstructive Pulmonary Disease
NCT01994096

Completed

Optimal Dosage of Caspofungin in Critically Ill Patients

Conditions: Critically Ill; Suspected Invasive Candidiasis
NCT02510053

Unknown status

Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit

Conditions: Invasive Fungal Infection
NCT00748345

Completed

Pharmacokinetics of Caspofungin in Burn Patients

Conditions: Thermal Injury
NCT01062165

Completed

Effect of Weight and/or Obesity on Caspofungin Drug Concentrations

Conditions: Obesity; Fungal Infection
NCT00404092

Completed

Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis

Conditions: Invasive Aspergillosis
NCT00292071

Completed

Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)

Conditions: Fungal Infection
NCT01260974

Unknown status

Caspofungin as Prophylaxis in High Risk Liver Transplantation Recipients

Conditions: Fungemia; Mycoses
NCT01045798

Terminated

Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)

Conditions: Invasive Candidiasis
NCT00635648

Completed

A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)

Conditions: Fungal Infection
NCT03580733

Not yet recruiting

Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis

Conditions: ICU Yeast Intra-abdominal Infection
NCT01501708

Unknown status

Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection

Conditions: Leukemia; Transplantation, Hematopoietic Stem Cell
NCT00095316

Terminated

Caspofungin Study for Fungal Infections in Adults in Critical Care Settings

Conditions: Candidiasis
NCT01165320

Completed

A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)

Conditions: Candidiasis, Esophageal; Candidiasis, Invasive; Aspergillosis
NCT00388167

Completed

Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection

Conditions: Candidiasis; Aspergillosis
NCT01945281

Terminated

Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)

Conditions: Candidiasis, Invasive
NCT02895529

Terminated

A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy

Conditions: Hematologic Neoplasms
NCT01307579

Completed

Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia; Adult Acute Monoblastic Leukemia; Adult Acute Monocytic Leukemia; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With Maturation; Adult Acute Myeloid Leukemia With Minimal Differentiation; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1; Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A; Adult Acute Myeloid Leukemia Without Maturation; Adult Acute Myelomonocytic Leukemia; Alkylating Agent-Related Acute Myeloid Leukemia; Childhood Acute Monoblastic Leukemia; Childhood Acute Monocytic Leukemia; Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myeloid Leukemia With Maturation; Childhood Acute Myeloid Leukemia With Minimal Differentiation; Childhood Acute Myeloid Leukemia Without Maturation; Childhood Acute Myelomonocytic Leukemia; Fungal Infection; Myeloid Neoplasm; Neutropenia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Myeloid Neoplasm